Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (97)

2024

  1. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

    Breast, Vol. 76

  2. A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer

    Future Oncology

  3. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases

    Annals of Oncology

  4. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

    ESMO Open, Vol. 9, Núm. 9

  5. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

    The Lancet Oncology, Vol. 25, Núm. 9, pp. 1231-1244

  6. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

    Nature Genetics, Vol. 56, Núm. 9, pp. 1878-1889

  7. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

    Blood

  8. Supportive oncodermatology practices in Europe and the USA

    Journal of the European Academy of Dermatology and Venereology

  9. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis

    Frontiers in Immunology, Vol. 15

2023

  1. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management

    International Journal of Dermatology, Vol. 62, Núm. 8, pp. 1020-1025

  2. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  3. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

  4. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

    Future oncology (London, England), Vol. 19, Núm. 35, pp. 2349-2359

2022

  1. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  2. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

    Journal of the European Academy of Dermatology and Venereology, Vol. 36, Núm. 3, pp. 332-350

  3. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

    Cancers, Vol. 14, Núm. 20

  4. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review

    Breast Cancer Research and Treatment, Vol. 194, Núm. 1, pp. 1-11

  5. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 29, pp. 3365-3376

  6. Shared decision making for patients with breast and gynecologic malignancies undergoing chemotherapy associated with persistent alopecia

    Gynecologic Oncology Reports, Vol. 44

  7. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

    JAMA Oncology, Vol. 8, Núm. 7, pp. 1047-1052